FXTAS (Fragile X-Associated Tremor/Ataxia Syndrome)
- Authors: Ostapchuk E.S.1,2, Malakhov M.V.2, Chikviladze S.S.2, Kuznetsov V.V.2, Morozova Y.S.1
-
Affiliations:
- Tyumen State Medical University
- The Regional Clinical Hospital №1, Tyumen
- Issue: Vol 16, No 3 (2025)
- Pages: 98-104
- Section: Case reports
- URL: https://journals.rcsi.science/clinpractice/article/view/352034
- DOI: https://doi.org/10.17816/clinpract676523
- EDN: https://elibrary.ru/TYCUEA
- ID: 352034
Cite item
Abstract
BACKGROUND: FXTAS Syndrome (Fragile X-Associated Tremor/Ataxia Syndrome) is a neurodegenerative disease with late onset, which manifests in men and women carrying the mutation in the FMR1 gene, located in the X-chromosome. The disease manifests with high phenotypic variability (tremor, cerebellar ataxia, parkinsonism, oculomotor disorders, cognitive and mental disorders). Due to the insufficient awareness among the physicians on this disease, FXTAS Syndrome patients often get incorrect diagnosis (essential tremor, Parkinson disease, multisystem atrophy, spinocerebellar ataxia etc.). CLINICAL CASE DESCRIPTION: The case presented is the patient aged 68 years with a severe past medical history (ischemic heart disease, post-infarction cardiosclerosis with the formation of post-infarction aneurism, arterial hypertension, pulmonary tuberculosis, chronic obstructive pulmonary disease, type 2 diabetes), in which the FXTAS Syndrome has first manifested with tremors, impaired coordination of motions, balance problems, cognitive disorders and affective disorders. The disease was confirmed by the genetic test (in the FMR1 gene, 96 CGG repeats were found). The patient’s daughter was examined with detecting the premutation of the FMR1 gene, while the grandson has a Martin-Bell syndrome. CONCLUSION: Neurologists and specialists of adjacent fields should keep in mind the FXTAS Syndrome (Fragile X-Associated Tremor/Ataxia Syndrome) and, in case of the patient having the corresponding symptoms, should rule out this rare neurodegenerative disease by arranging the genetic testing to reveal the mutation in the FMR1 gene.
Full Text
##article.viewOnOriginalSite##About the authors
Ekaterina S. Ostapchuk
Tyumen State Medical University; The Regional Clinical Hospital №1, Tyumen
Author for correspondence.
Email: ostapchukes2008@mail.ru
ORCID iD: 0000-0003-1176-4113
SPIN-code: 6877-6140
MD, PhD, Assistant Professor
Russian Federation, Tyumen; 55 Kotovskogo st, unit 3, Tyumen, 625023Maksim V. Malakhov
The Regional Clinical Hospital №1, Tyumen
Email: october27@mail.ru
ORCID iD: 0009-0000-4277-5857
Russian Federation, Tyumen
Sona S. Chikviladze
The Regional Clinical Hospital №1, Tyumen
Email: gvozdikaao@mail.ru
ORCID iD: 0009-0000-7328-0080
Russian Federation, Tyumen
Vitaly V. Kuznetsov
The Regional Clinical Hospital №1, Tyumen
Email: Vitalij.kuzneczov.1996@mail.ru
ORCID iD: 0009-0003-7721-1682
Russian Federation, Tyumen
Yuliya S. Morozova
Tyumen State Medical University
Email: dr.slavina@bk.ru
ORCID iD: 0009-0002-4422-4535
Russian Federation, Tyumen
References
- Cabal-Herrera AM, Tassanakijpanich N, Salcedo-Arellano MJ, Hagerman RJ. Fragile X-associated tremor/ataxia syndrome (FXTAS): pathophysiology and clinical implications. Int J Mol Sci. 2020;21(12):4391. doi: 10.3390/ijms21124391 EDN: TRLRPD
- Переверзева Д.С., Тюшкевич С.А., Горбачевская Н.Л., и др. Гетерогенность клинической картины при синдромах, ассоциированных с динамическими мутациями гена FMR1 // Журнал неврологии и психиатрии им. С.С. Корсакова. 2019. Т. 119, № 7. С. 103–111. [Pereverzeva DS, Tyushkevich SA, Gorbachevskaya NL, et al. Heterogeneity of clinical characteristics of FMR1-related disorders. S.S. Korsakov J Neurology Psychiatry. 2019;119(7):103–111]. doi: 10.17116/jnevro2019119071103 EDN: CHAHKE
- Красаков И.В., Литвиненко И.В., Дыскин Д.Е. Сложности диагностики синдрома тремора и атаксии, ассоциированного с ломкой Х-хромосомой // Известия Российской военно-медицинской академии. 2024. Т. 43, № 4. С. 481–487. [Krasakov IV, Litvinenko IV, Dyskin DE. Challenges in diagnosis of fragile X-associated tremor/ataxia syndrome. Russ Military Med Acad Rep. 2024;43(4):481–487]. doi: 10.17816/rmmar636637 EDN: OOKQUC
- Di Lazzaro G, Magrinelli F, Estevez-Fraga C, et al. X-linked parkinsonism: phenotypic and genetic heterogeneity. Mov Disord. 2021;36(7):1511–1525. doi: 10.1002/mds.28565 EDN: VSRBPT
- Pagano J, Lyakhovich A, Pallardo FV. Mitochondrial dysfunction in fragile X syndrome and fragile X-associated tremor/ataxia syndrome: prospect use of antioxidants and mitochondrial nutrients. Mol Biol Rep. 2024;51(1):480. doi: 10.1007/s11033-024-09415-7 EDN: ICCFVM
- Tassanakijpanich N, Hagerman RJ, Worachotekamjorn J. Fragile X premutation and associated health conditions: a review. Clin Genet. 2021;99(6):751–760. doi: 10.1111/cge.13924 EDN: ZVGSMO
- Adams JS, Adams PE, Nguyen D, et al. Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS). Neurology. 2007;69(9):851–859. doi: 10.1212/01.wnl.0000269781.10417.7b
- Dufour BD, Amina S, Martinez-Cerdeno V. FXTAS presents with upregulation of the cytokines IL12 and TNFα. Parkinsonism Relat Disord. 2021;82:117–120. doi: 10.1016/j.parkreldis.2020.11.026 EDN: IKUFBB
- Famula J, Ferrer E, Hagerman RJ, et al. Neuropsychological changes in FMR1 premutation carriers and onset of fragile X-associated tremor/ataxia syndrome. J Neurodev Discord. 2022;14(1):23. doi: 10.1186/s11689-022-09436-y EDN: ZFKBWH
- Salcedo-Arellano MJ, Johnson MD, McLennan YA, et al. Brain metabolomics in fragile X-associated tremor/ataxia syndrome (FXTAS). Cells. 2023;12(17):2132. doi: 10.3390/cells12172132 EDN: KEAZRG
- Tassone F, Protic D, Allen EG, et al. Insight and recommendations for fragile X-premutation-associated conditions from the fifth international conference on FMR1 premutation. Cells. 2023;12(18):2330. doi: 10.3390/cells12182330 EDN: GQTARI
- Cao Y, Peng Y, Kong HE, et al. Metabolic alterations in FMR1 premutation carriers. Front Mol Biosci. 2020;7:571092. doi: 10.3389/fmolb.2020.571092 EDN: OZFWTB
- Hagerman RJ, Hagerman P. Fragile X-associated tremor/ataxia syndrome: features, mechanisms and management. Nat Rev Neurol. 2016;12(7):403–412. doi: 10.1038/nrneurol.2016.82
- Tolosa E, Garrido A, Scholz SV, Poeve V. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 2021;20(5):385–397. doi: 10.1016/S1474-4422(21)00030-2
- McGinley MP, Goldschmidt CH, Ray-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8): 765–779. doi: 10.1001/jama.2020.26858 EDN: ZAYQGZ
- Grigsby J. The fragile X mental retardation 1 gene (FMR1): historical perspective, phenotypes, mechanism, pathology, and epidemiology. Clin Neuropsychol. 2016;30(6):815–833. doi: 10.1080/13854046.2016.1184652
- Stoker TB, Mason SL, Greenland JK, et al. Huntington‘s disease: diagnosis and management. Pract Neurol. 2022;22(1):32–41. doi: 10.1136/practneurol-2021-003074 EDN: GHPMKG
Supplementary files





